Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert E Kalb

Showing results (31-40 of 44) with videos related to

Pageof 5
Sort By:
Journal of the American Academy of Dermatology|December 14, 2011
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label studyAlice B Gottlieb, Robert E Kalb, Andrew Blauvelt, et al.
JAMA Dermatology|May 14, 2015
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Robert E Kalb, David F Fiorentino, Mark G Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|January 22, 2015
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapiesAlice B Gottlieb, Robert E Kalb, Richard G Langley, et al.
Journal of the American Academy of Dermatology|August 1, 2012
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasisHowa Yeung, Joy Wan, Abby S Van Voorhees, et al.
Journal of the American Academy of Dermatology|June 5, 2019
Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled studyMegan H Noe, Marilyn T Wan, Daniel B Shin, et al.
Archives of Dermatology|April 18, 2012
Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice settingJoel M Gelfand, Joy Wan, Kristina Callis Duffin, et al.
Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|September 28, 2014
Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical settingJunko Takeshita, Shuwei Wang, Daniel B Shin, et al.
The Journal of Investigative Dermatology|January 6, 2024
A Care Coordination Model to Prevent Cardiovascular Events in Patients with Psoriatic Disease: A Multicenter Pilot StudyWilliam B Song, Michael S Garshick, John S Barbieri, et al.
JAMA Dermatology|September 21, 2022
Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical TrialJoel M Gelfand, Daniel B Shin, April W Armstrong, et al.
Pageof 5

Showing results (31-40 of 44) with videos related to

Sort By:
Pageof 5
Journal of the American Academy of Dermatology|December 14, 2011
The efficacy and safety of infliximab in patients with plaque psoriasis who had an inadequate response to etanercept: results of a prospective, multicenter, open-label studyAlice B Gottlieb, Robert E Kalb, Andrew Blauvelt, et al.
JAMA Dermatology|May 14, 2015
Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Robert E Kalb, David F Fiorentino, Mark G Lebwohl, et al.
Journal of Drugs in Dermatology : JDD|January 22, 2015
Safety observations in 12095 patients with psoriasis enrolled in an international registry (PSOLAR): experience with infliximab and other systemic and biologic therapiesAlice B Gottlieb, Robert E Kalb, Richard G Langley, et al.
Journal of the American Academy of Dermatology|August 1, 2012
Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasisHowa Yeung, Joy Wan, Abby S Van Voorhees, et al.
Journal of the American Academy of Dermatology|June 5, 2019
Patient-reported outcomes of adalimumab, phototherapy, and placebo in the Vascular Inflammation in Psoriasis Trial: A randomized controlled studyMegan H Noe, Marilyn T Wan, Daniel B Shin, et al.
Archives of Dermatology|April 18, 2012
Comparative effectiveness of commonly used systemic treatments or phototherapy for moderate to severe plaque psoriasis in the clinical practice settingJoel M Gelfand, Joy Wan, Kristina Callis Duffin, et al.
Journal of the American Academy of Dermatology|November 6, 2007
From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasisMark Lebwohl, Jerry Bagel, Joel M Gelfand, et al.
Journal of the American Academy of Dermatology|September 28, 2014
Comparative effectiveness of less commonly used systemic monotherapies and common combination therapies for moderate to severe psoriasis in the clinical settingJunko Takeshita, Shuwei Wang, Daniel B Shin, et al.
The Journal of Investigative Dermatology|January 6, 2024
A Care Coordination Model to Prevent Cardiovascular Events in Patients with Psoriatic Disease: A Multicenter Pilot StudyWilliam B Song, Michael S Garshick, John S Barbieri, et al.
JAMA Dermatology|September 21, 2022
Association of Apremilast With Vascular Inflammation and Cardiometabolic Function in Patients With Psoriasis: The VIP-A Phase 4, Open-label, Nonrandomized Clinical TrialJoel M Gelfand, Daniel B Shin, April W Armstrong, et al.
Pageof 5